NeoDynamics to participate in Q&A on US launch on September 21

| 20 september, 2022 | 0 kommentarer

NeoDynamics today announced it would participate in a Q&A session with HC Andersen Capital on September 21 to discuss the company’s planned US launch of its innovative pulse biopsy system NeoNavia® after receiving approval from the US Food and Drug Administration, FDA, in September 2022.

“The FDA approval for NeoNavia earlier this month is a critical step for NeoDynamics as the US represents potentially the largest market for the product valued at $830 million by 2025,” said Anna Eriksrud, CEO of NeoDynamics. “The company is moving quickly to push its US strategy, which is similar to the plan that is now being executed on in Europe.”

NeoDynamics’s CEO Anna Eriksrud, and CFO Aaron Wong will present at the Q&A.

Participants can register here to join the event on September 21 at 11:00 to 11.30 CEST.

For further information, please contact:

Anna Eriksrud, CEO NeoDynamics AB, phone +46708 444 966 or e-mail [email protected]

CFO Aaron Wong, phone +46 735 972 011 or e-mail [email protected]

About NeoDynamics

NeoDynamics AB (publ) is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of breast cancer. The company’s first product NeoNavia®, a new innovative pulse biopsy system for ultrasound guided tissue sampling, is currently being introduced to the market. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia is evaluated for breast cancer diagnosis at leading clinics in UK, Germany, and Sweden. The pulse biopsy system has been used for tissue sampling in breast and axilla in over 500 patients. NeoDynamic´s share is listed on Nasdaq First North Growth Market Stockholm (ticker: NEOD). The company’s Certified Adviser is Redeye AB.

About NeoNavia

NeoNavia is a modern biopsy system with a completely new patented pulse technology intended for ultrasound-guided tissue sampling. It consists of a base unit, a handheld driver and three different types of biopsy needles. Each needle type is driven by the pulse technology providing a more controlled needle insertion and precise placement of the needle in the tumour whilst enabling high-quality tissue samples from both breasts and lymph nodes. The pulse biopsy system NeoNavia is designed to offer clinicians and patients accurate lesion targeting and high tissue yield for correct diagnosis and individualized treatment.

Kategori: Marknadsnyheter

Om skribenten ()

Tanalys är en sajt för investerare som med teknisk analys vill förbättra sin trading. Tanalys erbjuder teknisk analys från flera ledande analytiker, samt nyheter och utbildningar.

Lämna ett svar

Din e-postadress kommer inte publiceras.